-
How Did A Maligned Mylan Surprise To The Upside With 2017 Outlook?
Friday, March 10, 2017 - 12:02pm | 433Read More...“While new approvals hurt Mylan N.V. (NASDAQ: MYL) on price (during Q3), the company has defended share effectively; a point management highlighted but we believe has been underappreciated,” Barclays’ Douglas D. Tsao said in a note. The analyst maintains an Equal-Weight rating on...
-
Mylan's Q3 Report Tries, Fails To Shift Focus Away From EpiPen Controversy
Thursday, November 10, 2016 - 12:20pm | 250Read More...Mylan NV (NASDAQ: MYL) delivered a Q3 miss. Although management reiterated its 2018 earnings target, the company was not able to reverse sentiment “which has become increasingly negative in the wake of the Epipen controversy,” Barclays’ Douglas D. Tsao said in a report. He...
-
Barclays Initiates Protagonist At Overweight, Sees Upside Value In Proprietary Peptide Platform
Tuesday, September 6, 2016 - 8:56am | 326Read More...Protagonist Therapeutics Inc’s (NASDAQ: PTGX) lead asset PTG-100 in IBD has “significant end-market opportunity” and there is “upside value” in the company’s proprietary peptide platform, validated by four development-stage assets to date, Barclays’...
-
Patience May Be Needed In Aratana Therapeutics
Monday, November 30, 2015 - 10:31am | 372Read More...The share price of Aratana Therapeutics Inc (NASDAQ: PETX) has declined 65.6 percent year-to-date, almost touching its 52-week low on November 19. Barclays’ Douglas D. Tsao has maintained an Overweight rating on the company, while lowering the price target from $30 to $15. Although the stock...
-
Barclays Is Boosting Teva's PT
Thursday, April 9, 2015 - 4:01pm | 253Read More...Barclays raised its price target on Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) Thursday to $80 and maintained an Overweight rating. The analyst note followed a meeting with Teva CEO Siggi Olafsson. Analyst Douglas D. Tsao believed believed TEVA had a lot of things go its way...
-
UPDATE: Barclays Capital Reiterates on Actavis PLC Following Share Price Movement
Wednesday, October 30, 2013 - 10:58am | 147Read More...In a report published Wednesday, Barclays Capital analyst Douglas D. Tsao reiterated an Overweight rating on Actavis PLC (NYSE: ACT), and raised the price target from $175.00 to $190.00. In the report, Barclays Capital noted, “We believe the share price movement yesterday reflected ACT's 2014 EPS...
-
UPDATE: Barclays Capital Initiates Mallinckrodt at Equal-Weight on Differentiated Platform Value
Monday, July 8, 2013 - 8:57am | 155Read More...In a report published Monday, Barclays Capital analyst Douglas D. Tsao initiated coverage on Mallinckrodt (NYSE: MNK) with an Equal-Weight rating and $45.00 price target. In the report, Barclays Capital noted, “We believe MNK offers significant value through its differentiated platform in both...
